Onconetix, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
ONCO$3.47-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash | $3,716,072 | $5,220,654 |
| Accounts receivable, net | 43,725 | 296,866 |
| Inventories | 137,642 | 149,961 |
| Investor receivable | — | 50,000 |
| Prepaid expenses and other current assets | 431,915 | 349,293 |
| Total current assets | 4,329,354 | 6,066,774 |
| Property and equipment, net | 31,533 | 37,085 |
| Deferred offering costs | 225,000 | 225,000 |
| Operating right of use asset | 42,726 | 48,774 |
| Goodwill | 10,203,473 | 18,549,005 |
| Total assets | $14,832,086 | $24,926,638 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $1,532,885 | $1,757,695 |
| Accrued expenses | 279,121 | 341,881 |
| Notes payable | 247,196 | — |
| Operating lease liability, current | 24,415 | 24,412 |
| Contingent warrant liabilities | 24,978 | 26,590 |
| Derivative liabilities | 956,979 | 6,985,347 |
| Total current liabilities | 3,065,574 | 9,135,925 |
| Operating lease liability, net of current portion | 18,311 | 24,362 |
| Total liabilities | $3,083,885 | 9,160,287 |
| Commitments and Contingencies | ||
| Series C Redeemable Preferred Stock, $0.00001 par value, 10,000 shares authorized, 7 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 1,724 | 1,724 |
| Stockholders’ equity | ||
| Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2026 and December 31, 2025; 2,755,184 and 312,028 shares issued at March 31, 2026 and December 31, 2025, respectively; 2,755,154 and 311,998 shares outstanding at March 31, 2026 and December 31, 2025, respectively | 27 | 3 |
| Series D Preferred Stock, $0.00001 par value, 32,000 shares authorized at March 31, 2026 and December 31, 2025; 9,952 and 16,325 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively. | — | — |
| Series E Preferred Stock, $0.00001 par value, 10,000 shares authorized at March 31, 2026 and December 31, 2025; 7,581 and 7,813 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 148,242,874 | 147,836,001 |
| Treasury stock, at cost; 30 shares of common stock at March 31, 2026 and December 31, 2025 | (625,791) | (625,791) |
| Accumulated deficit | (135,429,433) | (131,214,558) |
| Accumulated other comprehensive loss | (441,200) | (231,028) |
| Total stockholders’ equity | 11,746,477 | 15,764,627 |
| Total liabilities, convertible preferred stock, and stockholders’ equity | $14,832,086 | $24,926,638 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.